Ourania Tatsis - 17 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2026
Net transactions value
-$1,582,118
Form type
4
Filing time
19 Feb 2026, 16:28:26 UTC
Previous filing
18 Feb 2026
Next filing
26 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tatsis Ourania EVP, Chief Reg. & Quality Off. C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 19 Feb 2026 0001789815

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +5,789 +13% $0.000000 51,921 17 Feb 2026 Direct F1
transaction VRTX Common Stock Tax liability $1,109,722 -2,294 -4.4% $483.75 49,627 17 Feb 2026 Direct
transaction VRTX Common Stock Sale $298,081 -609 -1.2% $489.46 49,018 17 Feb 2026 Direct F2
transaction VRTX Common Stock Sale $174,314 -368 -0.75% $473.68 48,650 18 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests in installments beginning on February 20, 2027.
F2 Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.